November 21, 2020 | 9:16pm
Regeneron Pharmaceuticals campus in Tarrytown, New York.
The treatment is aimed at those with mild cases of COVID-19, and not for those hospitalized as a result of the virus, the FDA said.
The treatment works by mimicking the body’s own immune system to prevent the infected from become severely ill.
Regeneron’s drug is a combination of two monoclonal antibodies. A similar drug developed by Eli Lilly & Co. gained FDA emergency clearance earlier this month.
However the Regeneron treatment may not be immediately widely available: the company has said it will have just 80,000 doses by the end of November.
Send your news and stories to us email@example.com or firstname.lastname@example.org and WhatsApp: +447747873668.
Before you go...
Democratic norms are being stress-tested all over the world, and the past few years have thrown up all kinds of questions we didn't know needed clarifying – how long is too long for a parliamentary prorogation? How far should politicians be allowed to intervene in court cases? To monitor these issues as closely as we have in the past we need your support, so please consider donating to The Climax News Room.